Related references
Note: Only part of the references are listed.Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma
Praveen K. Bommareddy et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2017)
Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial
Kevin J. Harrington et al.
ONCOTARGETS AND THERAPY (2016)
BRAF Inhibitor–Induced Antitumoral Granulomatous Dermatitis Eruption in Advanced Melanoma
Maria C. Garrido et al.
AMERICAN JOURNAL OF DERMATOPATHOLOGY (2015)
Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations
R. Sinha et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Robert H. I. Andtbacka et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Herpes zoster granulomatous dermatitis: histopathologic findings in a case series
Katalin Ferenczi et al.
JOURNAL OF CUTANEOUS PATHOLOGY (2015)
Morphea Developing at the Site of Healed Herpes Zoster
Tae Woo Noh et al.
ANNALS OF DERMATOLOGY (2011)
Granulocyte-macrophage colony stimulating factor-mediated innate responses in tuberculosis
Jacek Szeliga et al.
TUBERCULOSIS (2008)
Role of granulocyte/macrophage colony-stimulating factor in zymocel-induced hepatic granuloma formation
AA Wynn et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
Share Paper
